In last trading session, Olema Pharmaceuticals Inc (NASDAQ:OLMA) saw 0.39 million shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $12.21 trading at -$0.18 or -1.45% at ring of the bell on the day assigns it a market valuation of $699.27M. That closing price of OLMA’s stock is at a discount of -45.7% from its 52-week high price of $17.79 and is indicating a premium of 30.38% from its 52-week low price of $8.50. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.62 million shares which gives us an average trading volume of 934.80K if we extend that period to 3-months.
For Olema Pharmaceuticals Inc (OLMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.58 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Upright in the red during last session for losing -1.45%, in the last five days OLMA remained trading in the green while hitting it’s week-highest on Tuesday, 08/13/24 when the stock touched $12.21 price level, adding 5.57% to its value on the day. Olema Pharmaceuticals Inc’s shares saw a change of -12.97% in year-to-date performance and have moved 3.04% in past 5-day. Olema Pharmaceuticals Inc (NASDAQ:OLMA) showed a performance of -15.50% in past 30-days. Number of shares sold short was 8.04 million shares which calculate 13.26 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 54.78% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -96.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -96.56% for stock’s current value.
Olema Pharmaceuticals Inc (OLMA) estimates and forecasts
Statistics highlight that Olema Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -17.56% of value to its shares in past 6 months, showing an annual growth rate of 29.44% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -105.28% during past 5 years.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
Insiders are in possession of 3.63% of company’s total shares while institution are holding 100.68 percent of that, with stock having share float percentage of 104.47%. Investors also watch the number of corporate investors in a company very closely, which is 100.68% institutions for Olema Pharmaceuticals Inc that are currently holding shares of the company. BVF INC/IL is the top institutional holder at OLMA for having 9.14 million shares of worth $103.42 million. And as of 2024-03-31, it was holding 16.4391 of the company’s outstanding shares.
The second largest institutional holder is PARADIGM BIOCAPITAL ADVISORS LP, which was holding about 7.9 million shares on 2024-03-31. The number of shares represents firm’s hold over 14.2217 of outstanding shares, having a total worth of $89.47 million.
On the other hand, Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2024 , the former fund manager was holding 1.31 shares of worth $16.06 million or 2.30% of the total outstanding shares. The later fund manager was in possession of 1.02 shares on Jun 30, 2024 , making its stake of worth around $12.51 million in the company or a holder of 1.79% of company’s stock.
